Status:
UNKNOWN
Atorvastatin in Myeloma
Lead Sponsor:
Bayside Health
Conditions:
Myeloma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.
Eligibility Criteria
Inclusion
- Myeloma in remission
Exclusion
- Adverse events (AEs) to statin, already on a statin, or contraindication to statin
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00164086
Last Update
October 11 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3181